2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
These guidelines address cardiovascular care for cancer patients before, during, and after treatment, focusing on prevention, surveillance, and management of cancer therapy-related cardiovascular toxicity. They recommend baseline risk assessment, personalized surveillance protocols, and management strategies for various cancer therapies and cardiovascular conditions, emphasizing a multidisciplinary approach and patient involvement in care.
Lyon-2022--esc-guidelines-on-cardio-oncology-.pdf